# ü´Å Pulmonary Medicine: Triple Inhaler Therapy in Severe COPD

#### ‚úÖ True Statements
1. In **chronic obstructive pulmonary disease (COPD)**, treatment is guided by the severity of symptoms and the frequency and severity of exacerbations.  
2. Patients with **‚â•2 moderate COPD exacerbations** or **‚â•1 exacerbation requiring hospitalization per year** are categorized as **high risk (GOLD group E)** regardless of symptom severity.  
3. Standard therapy for **GOLD group E COPD** is combination bronchodilator therapy with a **long-acting Œ≤2-agonist (LABA)** and a **long-acting muscarinic antagonist (LAMA)**.  
4. In patients with **COPD and frequent exacerbations**, adding an **inhaled glucocorticoid (ICS)** to LABA and LAMA therapy reduces symptoms and exacerbations, despite an increased risk of pneumonia.  
5. Patients with **blood eosinophil count >300/¬µL (0.30 √ó 10‚Åπ/L)** are most likely to benefit from the addition of an inhaled glucocorticoid.  
6. In **severe COPD with frequent exacerbations and eosinophilia**, the most appropriate next step is **triple therapy** with an **inhaled glucocorticoid + LABA + LAMA**.  
7. **Roflumilast**, a selective phosphodiesterase-4 inhibitor, reduces exacerbations in patients with **severe COPD and chronic bronchitis** who continue to exacerbate with **FEV1 <50% predicted**.  
8. During acute COPD exacerbations, **oral glucocorticoids** decrease treatment failure, hospital length of stay, and risk of early relapse.  
9. A **short course of prednisone (40 mg daily for 5 days)** is usually equivalent in efficacy to longer courses, higher doses, or intravenous glucocorticoid administration.  
10. In patients with **severe COPD and eosinophilia**, continuing dual therapy with LABA and LAMA **without adding an inhaled glucocorticoid** is not appropriate.  
11. In patients with **severe COPD**, **triple inhaler therapy with LABA, LAMA, and inhaled glucocorticoid** may reduce exacerbations and provide additional symptom benefit, especially in patients with **eosinophilia**.

#### üí¨ Extra
2. GOLD categorization stratifies risk to guide therapy; group E reflects the highest risk patients.  
4. Although ICS increases pneumonia risk, the net benefit in frequent exacerbators is favorable.  
7. Roflumilast is reserved for chronic bronchitis phenotype and low FEV1.  
9. Evidence supports shorter steroid courses for COPD exacerbations to minimize adverse effects.

#### üè∑Ô∏è Tags
#PulmonaryMedicine #COPD #TripleTherapy #InhaledGlucocorticoid #LABA #LAMA #Roflumilast #Eosinophilia #Exacerbations

#### üìö Reference
Global Initiative for Chronic Obstructive Lung Disease. *Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.* 2025 Report. https://goldcopd.org/2025-gold-report/. Accessed May 20, 2025.

#### üÜî Question ID
PMMCQ24053

#### üïí Last Updated
June 2025

---

#### üìñ Related Text
MKSAP 19: Pulmonary Medicine ‚Äî Airways Disease, Chronic Obstructive Pulmonary Disease, Management of COPD, Pharmacologic Therapy for COPD ‚Äî *Inhaled Corticosteroids (Glucocorticoids)*

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. Inhaled glucocorticoids are typically used **only in combination with a long-acting bronchodilator** for COPD treatment.  
2. Inhaled glucocorticoids are **not used alone** unless the patient is unable to use long-acting bronchodilators.  
3. Inhaled glucocorticoids **improve lung function**, **reduce symptoms**, and **reduce exacerbations** in **moderate to severe COPD**, despite an increased pneumonia risk.  
4. In **severe COPD**, **triple therapy (LABA + LAMA + ICS)** may reduce exacerbations, improve symptoms, and, when combined into a **single inhaler**, decrease mortality.  
5. Guidelines recommend adding inhaled glucocorticoids to long-acting bronchodilator therapy if the **blood eosinophil count >300/¬µL (0.30 √ó 10‚Åπ/L)** or if the patient has **asthmatic features with COPD**.

#### üí¨ Extra
1. The combination approach reflects synergistic effects of bronchodilation and anti-inflammatory therapy.  
4. Mortality benefit has been demonstrated when triple therapy is delivered in a single inhaler device.

#### üè∑Ô∏è Tags
#COPD #TripleTherapy #InhaledGlucocorticoid #LABA #LAMA #Eosinophilia #AsthmaCOPDOverlap

---

#### üóæ Supplemental Tables

<!-- Recommended Pharmacologic Management of COPD by GOLD Classification -->
<table>
  <caption><strong>Recommended Pharmacologic Management of COPD by GOLD Classification</strong></caption>
  <thead>
    <tr>
      <th>Patient Group</th>
      <th>Recommended Therapy</th>
      <th>Alternative or Additional Therapy</th>
      <th>Other Considerations</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>A</td>
      <td>
        Short-acting bronchodilator<br>
        <em>or</em><br>
        Long-acting bronchodilator
      </td>
      <td>
        Evaluate effect of therapy and continue, stop, or try alternative bronchodilator as appropriate
      </td>
      <td>
        All patients in this group should receive bronchodilator therapy based on its effect on dyspnea; therapy should be continued if symptomatic benefit is documented
      </td>
    </tr>
    <tr>
      <td>B</td>
      <td>LABA + LAMA</td>
      <td>
        If a LABA+LAMA combination is not appropriate, there is no evidence to recommend one agent over the other; choice should depend on the patient's perception of symptom relief
      </td>
      <td>
        <ul>
          <li>Long-acting inhaled bronchodilators are superior to short-acting bronchodilators received as needed</li>
          <li>No evidence supports use of one class of long-acting bronchodilators over another for initial relief of symptoms in this group</li>
          <li>Patients in group B are likely to have comorbidities that affect symptoms and prognosis, and these should be investigated</li>
        </ul>
      </td>
    </tr>
    <tr>
      <td>E</td>
      <td>
        LABA + LAMA<br>
        LABA + LAMA + ICS<sup>a</sup>
      </td>
      <td>
        If exacerbations continue, consider:<br>
        <ul>
          <li><strong>Roflumilast</strong> (patients with an FEV1 &lt;50% of predicted and chronic bronchitis, particularly if ‚â•2 exacerbations or ‚â•1 hospitalization in past year)</li>
          <li><strong>Macrolide therapy</strong> (best evidence supports use of azithromycin)</li>
          <li><strong>Dupilumab</strong> (patients with chronic bronchitis)<sup>a</sup></li>
        </ul>
      </td>
      <td>
        Patients with concomitant asthma should receive an ICS
      </td>
    </tr>
  </tbody>
</table>

<p><em>GOLD = Global Initiative for Chronic Obstructive Lung Disease; ICS = inhaled corticosteroid (glucocorticoid); LABA = long-acting Œ≤<sub>2</sub>-agonist; LAMA = long-acting muscarinic antagonist.</em></p>
<p><em><sup>a</sup> Consider if eosinophil count ‚â•300/¬µL (0.30 √ó 10<sup>9</sup>/L).</em></p>
<p><em>Information from Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2025 Report. <a href="https://goldcopd.org/2025-gold-report/">https://goldcopd.org/2025-gold-report/</a>. Accessed May 20, 2025.</em></p>

---

#### ‚úÖ True Statements (from Table: Recommended Pharmacologic Management of COPD by GOLD Classification)
1. **GOLD group A** COPD should be treated with a **short-acting or long-acting bronchodilator**.
2. In **GOLD group A** COPD, bronchodilator therapy should be **continued if symptomatic benefit is documented** and may be **stopped or changed** based on response.
3. **GOLD group B** COPD initial therapy is **LABA + LAMA**.
4. If **LABA + LAMA** is not appropriate in **GOLD group B**, **no evidence** favors **LABA** over **LAMA** monotherapy; the **choice depends on patient-perceived symptom relief**.
5. In **GOLD group B**, **long-acting inhaled bronchodilators** are **superior** to **short-acting bronchodilators used as needed**.
6. In **GOLD group B**, **no evidence** supports using **one class of long-acting bronchodilator over the other** for initial symptom relief.
7. **GOLD group B** patients are **likely to have comorbidities** that affect symptoms and prognosis, and **these should be investigated**.
8. **GOLD group E** COPD recommended therapy includes **LABA + LAMA**, with consideration of **LABA + LAMA + ICS** when appropriate.
9. If exacerbations persist in **GOLD group E**, consider **roflumilast** for patients with **FEV1 &lt;50% predicted** and **chronic bronchitis**, especially with **‚â•2 exacerbations or ‚â•1 hospitalization** in the previous year.
10. If exacerbations persist in **GOLD group E**, consider **macrolide therapy**, with the **best evidence for azithromycin**.
11. If exacerbations persist in **GOLD group E**, consider **dupilumab** for **patients with chronic bronchitis** (see footnote criteria).
12. **Patients with concomitant asthma** should **receive an inhaled corticosteroid (ICS)**.